• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    2.190 +0.010 (+0.46%)
    Streaming Delayed Price Updated: 2:17 PM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 99,428
    Open 2.250
    Bid (Size) 2.180 (500)
    Ask (Size) 2.230 (200)
    Prev. Close 2.180
    Today's Range 2.130 - 2.300
    52wk Range 1.110 - 4.703
    Shares Outstanding 11,184,423
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript ↗
    LP-300 shows strong efficacy in lung cancer while operating losses shrink 25%. 
    Via The Motley Fool
    Topics Earnings
    NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property

    Performance

    YTD
    -29.6%
    -29.6%
    1 Month
    -21.5%
    -21.5%
    3 Month
    -33.8%
    -33.8%
    6 Month
    -23.7%
    -23.7%
    1 Year
    -50.1%
    -50.1%

    More News

    Read More
    News headline image
    Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
    From New to The Street
    Via ACCESS Newswire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
    From New to The Street
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
    From New to The Street
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street(R) to Broadcast Show #762 Tonight on Bloomberg Television at 6:30 PM ET, Featuring Envoy Medical (NASDAQ:COCH), AlphaCompute (NASDAQ:ALP), RHINO Bitcoin (OTC PINK:RHNO), and Big Sky Industrial (NASDAQ:BSIN)
    From New to The Street
    Via ACCESS Newswire
    News headline image
    New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group
    From New to The Street
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Launches AI-Powered ZetaOmics Computational Biology Platform
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
    From New to The Street
    Via ACCESS Newswire
    News headline image
    New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
    From New to The Street
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
    Via ACCESS Newswire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
    Via ACCESS Newswire
    News headline image
    Lantern Pharma (LTRN) Q1 2025 Earnings Transcript ↗
    Via The Motley Fool
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Lantern Pharma Inc. - Common Stock publicly traded?
    Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
    What exchange does Lantern Pharma Inc. - Common Stock trade on?
    Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
    The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
    What is the current price of Lantern Pharma Inc. - Common Stock?
    The current price of Lantern Pharma Inc. - Common Stock is 2.190
    When was Lantern Pharma Inc. - Common Stock last traded?
    The last trade of Lantern Pharma Inc. - Common Stock was at 08/27/26 02:17 PM ET
    What is the market capitalization of Lantern Pharma Inc. - Common Stock?
    The market capitalization of Lantern Pharma Inc. - Common Stock is 24.49M
    How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
    Lantern Pharma Inc. - Common Stock has 24M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.